The main exchange for listing psychedelics companies, Horizons Psychedelic Stock Index ETF, has completed its first quarterly rebalance of its holdings. Horizons ETFs has over US$17.5 billion of assets under management and 88 ETFs ...
Last week, the Australian government announced it would provide $15m of funding to support research into psychedelic medicines and their impact on treating mental health conditions. The Mental Illness Grant Opportunity represents a new ...
Laurie Higbed, Ben Sessa and Steve O’Brien: Awakn Life Sciences | Photograph: Joel Redman/The Guardian Awakn Life Sciences has opened a clinic offering ketamine-assisted psychotherapy in the UK, becoming the first of its kind in the ...
Recently published results of The Global Drug Survey have revealed the behaviour and experiences of people using the likes of psilocybin, LSD, DMT MDMA and other psychedelics to aid their wellbeing and mental health. The online study ...
Researchers from Imperial College London have carried out the largest placebo-controlled trial into psychedelics to date and found that small doses of LSD boost the psychology of users in a manner of ways. However, when the researchers ...
During The PSYCH Symposium in November 2020, a panel of leading scientists discussed their work in the field of psychedelic medicines as well as the research they had conducted on microdosing and the impact it has on the human body. ...
During The PSYCH Symposium in November 2020, a panel of leading experts operating in psychedelics sector, discussed the cultural challenge of commercialising the likes of psilocybin, DMT and LSD. This discussion, featuring a number of ...
Last week, the world’s first exchange-traded fund for psychedelic medicines companies made its debut in Toronto, as the investment sector aims to capitalise on the rapidly developing interest in prospective mental health ...
During The PSYCH Symposium in November 2020, a panel of leading experts,operating in psychedelics sector discussed the advancement of research on psilocybin. The groundbreaking, rapid progress being made in a number of regions across ...
During The PSYCH Symposium in November 2020, Professor David Nutt, chairman of Awakn Life Sciences, founder of Drug Science and the director of neuropsychopharmacology at Imperial College London, delivered a virtual keynote speech on ...